Skip to main content
Dryad

Data from: Modeling stereospecific drug interactions with beta-adrenergic receptor

Data files

Apr 21, 2025 version files 16.76 GB

Click names to download individual files Select up to 11 GB of files for zip download

Abstract

Beta-adrenergic receptors (βARs) are G protein-coupled receptors that regulate processes such as heart rhythm and vascular tone by binding agonists like norepinephrine, inducing downstream signaling pathways. Beta blockers antagonize βARs, reducing heart rate and lowering vascular tone. We developed a new Rosetta structural modeling protocol to create state-specific models of β1AR and investigated its atomistic-scale interactions with beta-blocker stereoisomers: d- and l-sotalol, as well as R- and S-propranolol. Our combined molecular dynamics (MD) simulations and docking protocol effectively captured the differences in stereoisomer specificity in binding to β1AR. Binding energetics results favored l-sotalol and S-propranolol, consistent with experimental findings showing d-sotalol has significantly lower affinity for beta-adrenergic receptors than l-sotalol. The entropy term was identified as the primary factor driving enantiomer binding specificity, with higher entropy costs for d-sotalol and R-propranolol due to their unfavorable chiral structures. Simulations demonstrated that subtle differences in enantiomers lead to distinct β1AR conformations, with d and R enantiomers causing larger structural changes than l and S enantiomers. Specifically, sotalol affects ICL2 and propranolol affects ICL1. The distance between TM4 and TM6 also exhibited different distributions among enantiomers, indicating varying strengths in stabilizing specific GPCR states. The outer vestibule of the receptor may play a crucial role in the stereoselectivity of small drugs, evidenced by fewer contacts between d-sotalol and ECL2 residues compared to l-sotalol. This study provides a foundation for understanding the stereospecificity of beta blockers for βARs, which are important pharmacological targets, and could be extended to other drug classes and receptor types.